GLP-1 & Weight Loss
The breakthrough metabolic peptides driving the modern weight-loss revolution — GLP-1, dual, and triple agonists.
GLP-1 receptor agonists like Semaglutide (Ozempic, Wegovy) and the dual-agonist Tirzepatide (Mounjaro, Zepbound) have transformed metabolic medicine, producing 15-25% body-weight reductions in clinical trials. Retatrutide, a triple agonist, shows the strongest data yet. Slow titration is essential to manage GI side effects.
Peptides in this category (5)
Cagrilintide
Long-acting amylin analogue that enhances satiety; often paired with semaglutide (CagriSema) for additive fat loss.
Evidence Level
Retatrutide
Next-generation triple agonist (GLP-1 / GIP / glucagon) producing the largest weight-loss results seen in trials to date.
Evidence Level
Semaglutide
The widely studied GLP-1 agonist behind modern weight-loss medicine — strong appetite control and metabolic benefits.
Evidence Level
Survodutide
GLP-1 / glucagon dual agonist studied for weight loss and metabolic-associated fatty liver disease (MASH).
Evidence Level
Tirzepatide
Dual GLP-1 / GIP agonist for powerful appetite suppression, blood-sugar control, and fat loss.
Evidence Level
3 more peptides in this category
Weekly titration schedules, syringe-unit dosing, and side-effect management guides are available to Core and Pro subscribers.
Start Free Trial7 days free. Then $24/month.
Explore Other Categories
PepCompass provides educational information only. Nothing on this platform constitutes medical advice. Always consult a licensed healthcare provider before starting any peptide protocol.